[1] [1] WU H S, MCSWEENEY M. Cancer-related fatigue: “it's so much more than just being tired”[J]. Eur J Oncol Nurs, 2007, 11(2): 117-125. DOI:10.1016/j.ejon.2006.04.037.

[2] [2] SUSANNE K, MICHAEL F, THOMAS S,et al. Predictors of fatigue in cancer patients: a longitudinal study[J]. Support Care Cancer, 2019, 27(9): 3463-3471. DOI:10.1007/s00520-019-4660-4.

[3] [3] NOWICKI A, PIEKARSKA J, FARBICKA E. The assessment of cancer-related fatigue syndrome in patients with lung cancer during palliative chemotherapy[J]. Adv Respir Med, 2017, 85(2): 69-76. DOI:10.5603/ARM.2017.0013.

[4] [4] FOX R S, ANCOLI-ISRAEL S, ROESCH S C,et al. Sleep disturbance and cancer-related fatigue symptom cluster in breast cancer patients undergoing chemotherapy[J]. Support Care Cancer,2020, 28(2): 845-855. DOI:10.1007/s00520-019-04834-w.

[6] [6] WANG X S, FAIRCLOUGH D L, LIAO Z X,et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms[J]. J Clin Oncol, 2006,24(27): 4485-4491. DOI:10.1200/JCO.2006.07.1126.

[7] [7] WOOD L S, MOLDAWER N P, LEWIS C. Immune checkpoint inhibitor therapy: key principles when educating patients[J]. Clin J Oncol Nurs, 2019, 23(3): 271-280. DOI:10.1188/19.CJON.271-280.

[8] [8] WANG Y C, ZHOU S H, YANG F,et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis[J]. JAMA Oncol, 2019, 5(7): 1008-1019. DOI:10.1001/jamaoncol.2019.0393.

[13] [13] POORT H, PETERS M J, VAN DER GRAAF W A,et al. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial[J]. Ann Oncol, 2020, 31(1):115-122. DOI:10.1016/j.annonc.2019.09.002.

[14] [14] MUKHOPADHYAY S, DUTTA P, BANERJEE S,et al. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study[J]. Future Oncol, 2021, 17(16): 2041-2056. DOI:10.2217/fon-2020-0834.

[15] [15] GARCA-GONZLEZ D, ROMERO-ELAS M, LVAREZ-BUSTOS A,et al. Cancer-related fatigue and circulating biomarkers in breast cancer survivors[J]. Biol Res Nurs, 2024, 26(2): 270-278. DOI:10.1177/10998004231215777.

[16] [16] WANG B C, CAO R B, LI P D,et al. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: a systematic review and meta-analysis[J]. Cancer Med, 2019, 8(13): 5969-5978. DOI:10.1002/cam4.2510.

[17] [17] ABDEL-RAHMAN O, HELBLING D, SCHMIDT J,et al. Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis[J]. Clin Oncol, 2016, 28(10): e127-138. DOI:10.1016/j.clon.2016.06.008.

[18] [18] CORTELLINI A, VITALE M G, DE GALITIIS F,et al. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice[J/OL]. J Transl Med,2019, 17(1): 376[2024-12-02]. https://pubmed.ncbi.nlm.nih.gov/31730009/. DOI:10.1186/s12967-019-02132-x.

[19] [19] WEI X L, REN C, WANG F H, et al. A phase Ⅰ study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors[J]. Cancer Commun, 2020, 40(8): 345-354. DOI:10.1002/cac2.12068.